Generics BulletinANI Pharmaceuticals forecasts a roughly 25% growth in revenue for 2024, on the back of strong performance of its generic and rare disease businesses. As of now, the company’s total net revenue guidanc
Generics BulletinANI Pharmaceuticals has championed its “superior R&D capabilities” after launching the first US generic version of Takeda’s Motegrity (prucalopride) tablets. The US firm’s launch – via its Noviti
Generics BulletinANI Pharmaceuticals has again beat some analyst estimates, receiving praise at a transformative point for the company following its acquisition of Alimera Sciences earlier in autumn. Notably, ANI mana
Generics BulletinANI Pharmaceuticals and Alimera Sciences say they will close their previously agreed $380m+ merger before the market opens on 16 September, with the announcement coming just 24 hours after eye-diseas